GlassScriptPhysician profile
Heather Ann Menees
NPI 1831643113
$6,358.71
in general payments reported to CMS, 2019-2025
46 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,854 · 2022: $1,391 · 2023: $1,011 · 2024: $1,072 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,114.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,121.40 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $933.74 | 2021-2025 | |
| Amgen INC. | $720.60 | 2021-2025 | Evenity, Repatha, Otezla |
| Astellas Pharma US INC | $430.88 | 2021-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $294.94 | 2021-2025 | Zepbound, Mounjaro, Kisunla |
| Glaxosmithkline, LLC. | $276.08 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Biohaven Pharmaceuticals, INC. | $230.57 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $212.19 | 2021-2024 | Farxiga, Airsupra |
| Pfizer INC. | $188.52 | 2022-2025 | |
| Abbott Laboratories | $175.84 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amarin Pharma, INC. | $171.20 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $166.16 | 2021-2025 | Trintellix |
| Lundbeck LLC | $139.84 | 2021-2025 | Rexulti, Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.84 | 2022-2025 | Xifaxan, Cycloset |
| Tris Pharma INC | $88.29 | 2023-2025 | Dyanavel Xr |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Menees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.